+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

UK Long-Acting Bronchodilator Market 2019-2025

  • ID: 4991496
  • Report
  • January 2020
  • Region: United Kingdom
  • Orion Market Research Private Limited

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Novartis AG
  • Pulmatrix Inc.
  • ResMed Corp.
  • Savara, Inc.
  • MORE
UK Long-Acting Bronchodilator Market Size, Share & Trends Analysis Report by Route of Administration (Oral, Nasal, Parenteral, and Inhalation), by Application (Asthma and Chronic Obstructive Pulmonary Disease (COPD)), by End-User (Homecare and Hospitals and Clinics) and Forecast 2019-2025.

UK long-acting bronchodilator market is anticipated to grow at a substantial rate of around 1.5% during the forecast period. Inhalers are used for providing medication to the patients through the lungs. These are used for the treatment of the patient from asthma attacks and other respiratory ailments. As the prevalence of asthma and other diseases increases across UK, the demand for long-acting bronchodilators is also expected to increase for treatment purposes. As per the International Monetary Fund GDP of the country was $2.9 trillion in 2017. UK comprises England, Scotland, Wales and Northern Ireland. The total population of the country in 2017 was 65 million, out of which about 18% are of the geriatric population. Mortalities related to asthma and COPD are high in UK and due to these a significant investment by the government and people can be forecast in the near future.

UK long-acting bronchodilator market is segmented on the basis of route of administration, application, and end-user. Based on the route of administration, the market is classified into oral, nasal, parenteral, and inhalation. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. The asthma disease application segment dominated the regional market in 2018 and is further estimated to follow the same trend over the forecast period. This is mainly due to the high prevalence of asthma in the country and rising demand for its various treatment solutions. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.

Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing long-acting bronchodilator to cater to a wide range of customers within the region and across the globe. The major players of the UK long-acting bronchodilator market include Boehringer Ingelheim International GmbH, AstraZeneca PLC, GlaxoSmithKline PLC, Novartis AG, Teva Pharmaceuticals Industries Ltd., and Vitalograph Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.

Research Methodology

The market study of the UK long-acting bronchodilator market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors.

Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report is intended for long-acting bronchodilator manufacturers, contract research organizations (CROs), healthcare sector, market research firms, and government organizations, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:
1. UK Long-Acting Bronchodilator Market Research and Analysis by Route of Administration
2. UK Long-Acting Bronchodilator Market Research and Analysis by Application
3. UK Long-Acting Bronchodilator Market Research and Analysis by End-User
The Report covers:
  • Comprehensive research methodology of the UK long-acting bronchodilator market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the UK long-acting bronchodilator market.
  • Insights about market determinants which are stimulating the UK long-acting bronchodilator market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Novartis AG
  • Pulmatrix Inc.
  • ResMed Corp.
  • Savara, Inc.
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. UK Long-Acting Bronchodilator Market by Route of Administration
5.1.1. Oral
5.1.2. Nasal
5.1.3. Parenteral
5.1.4. Inhalation
5.2. UK Long-Acting Bronchodilator Market by Application
5.2.1. Asthma
5.2.2. Chronic Obstructive Pulmonary Disease (COPD)
5.3. UK Long-Acting Bronchodilator Market by End-User
5.3.1. Homecare
5.3.2. Hospitals and Clinics

6. Company Profiles
6.1. Adamis Pharmaceuticals Corp.
6.2. AstraZeneca PLC
6.3. Boehringer Ingelheim International GmbH
6.4. GlaxoSmithKline PLC
6.5. Novartis AG
6.6. ResMed Corp.
6.7. Pulmatrix Inc.
6.8. Savara, Inc.
6.9. Sunovion Pharmaceuticals
6.10. Teva Pharmaceuticals Industries Ltd.
6.11. Vitalograph Ltd.
Note: Product cover images may vary from those shown
  • Adamis Pharmaceuticals Corp.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline PLC
  • Novartis AG
  • ResMed Corp.
  • Pulmatrix Inc.
  • Savara, Inc.
  • Sunovion Pharmaceuticals
  • Teva Pharmaceuticals Industries Ltd.
  • Vitalograph Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll